Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM. Boggild MK, Cheung AM. Ann Intern Med 2021;174:JC106.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Boggild MK, Cheung AM. Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM. Ann Intern Med 2021;174:JC106.
PMID: 34487441